Evidence Hub

Case report: rapid intracranial response with tarlatamab in patients with untreated brain metastases from small cell lung cancer-- a real-world case series

Bingnan Zhang, Komal Shah, Mitchell Parma, Kai-Wen Wang, E. Singhi, Whitney E. Lewis, M. Rivera, Mehmet Altan et al.

Journal of Thoracic Oncology, 2025

10 participants · 24 citations

Abstract

Small cell lung cancer (SCLC) has the highest propensity for brain metastases among all malignancies. Systemic treatment for SCLC, particularly in the setting of brain metastases, is very limited. Tarlatamab, the CD3/DLL3 bispecific T cell engager, has changed the treatment landscape of relapsed SCLC since its FDA approval in May 2024. Patients with treated and stable brain metastases were included in the phase 1 DeLLPhi-300 trial and phase 2 DeLLPhi-301 trials of tarlatamab. However, it remains unknown if tarlatamab is safe and efficacious in the setting of untreated, active/symptomatic brain metastases. Our case series provides, to our knowledge, the first reported evidence of the safety and efficacy of tarlatamab in patients with untreated brain metastases. In our cohort of 10 patients with relapsed SCLC and untreated brain metastases, including those with symptomatic intracranial disease and one with suspected leptomeningeal disease (LMD), clinical response or stability were seen in 90% of patients. We present several cases in which rapid, dramatic radiographic responses and clinical improvement were observed in patients with innumerable growing brain metastases (>20 lesions) who would otherwise require whole brain radiation, suggesting that tarlatamab can control intracranial metastases as monotherapy, potentially sparing or deferring the need for brain radiation.

How strong is the evidence?

Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health. Reported size: 10 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free